Praziquantel efficacy and post-treatment reinfection and incidence of Schistosoma mansoni among school-aged children in Northern Uganda: a 24-week cohort study in a high transmission focus
John Paul Byagamy, Robert Opiro, Margaret Nyafwono, Harriet Angwech, Geoffrey Maxwell Malinga, Richard Echodu, Emmanuel Igwaro Odongo-Aginya · 2026
Read Praziquantel efficacy and post-treatment reinfection and incidence of Schistosoma mansoni among school-aged children in Northern Uganda: a 24-week cohort study in a high transmission focus by John Paul Byagamy, Robert Opiro, Margaret Nyafwono, Harriet Angwech, Geoffrey Maxwell Malinga, Richard Echodu, Emmanuel Igwaro Odongo-Aginya (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13471520.txt.
Description
Byagamy and colleagues measured how well the deworming drug praziquantel works, and how fast children get reinfected, in a high-transmission corner of northern Uganda. Their 2026 cohort study screened 802 primary school children aged 5 to 16 for Schistosoma mansoni, the blood fluke behind intestinal schistosomiasis, and followed them for 24 weeks.
Baseline infection stood at 34.8% of the children tested, and the 279 infected children received a single standard dose. That dose cured 82.1% of infections at four weeks but cut egg output by only 32.9% overall, while a second dose for non-responders cured 93.9% of them. By 24 weeks, 7.7% of cured children were reinfected and true new infections ran at 5.0% of the uninfected group, prompting a call for twice-yearly dosing.
Catalog record
| CREATOR | John Paul Byagamy, Robert Opiro, Margaret Nyafwono, Harriet Angwech, Geoffrey Maxwell Malinga, Richard Echodu, Emmanuel Igwaro Odongo-Aginya |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 51 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |